Endo Buys Six Injectables Amid Shattering Decline In EBITDA Guidance

‘Our Focus Is On Driving Long-Term EBITDA Growth,’ Endo Insists

17 May 2022

Endo maintains that it will continue to drive revenue and EBITDA growth via business development opportunities, after the advent of generic competition to its lucrative Vasostrict injectable led the firm to disclose potentially catastrophic Q2 profitability guidance.

Expanding portfolio is Endo's first priority • Source: OleksandrShnuryk/Shutterstock

Endo International has expanded its pipeline of differentiated ready-to-use sterile injectables for the hospital setting, acquiring six development-stage product candidates from longtime partner Nevakar Injectables for $35m.

The injectables are in “various stages of development,” Endo noted, “with the first launch expected in 2025